Rare Disease Therapeutics Inc., a Franklin, Tenn.-based company focused on developing orphan products, has won FDA approval for Anascorp, the first specific treatment for a scorpion sting by Centruroides scorpions in the U.S. Read More
Amid the overall U.S. market plunge tipped by economic uncertainty on Thursday, the biotech sector suffered an additional gut check on the heels of Dendreon Corp.'s second quarter miss. Read More
Prolor Biotech Inc., of Nes-Ziona, Israel, said results from a Phase II trial showed that a single weekly injection of its long-acting CTP-modified version of human growth hormone (hGH-CTP) has the potential to replace seven consecutive daily injections of currently marketed hGH in adults with a growth-hormone deficiency. Read More
Shares in Seattle's Dendreon Corp. plummeted 67.4 percent Thursday after it broke the news that sales of Provenge (sipuleucel-T) were lower than expected. Dendreon reported just $49.6 million in revenues for the prostate cancer vaccine, coming in $8 million lower than consensus estimates of $57.7 million. Dendreon attributed the miss to a lack of understanding among physicians about how to get reimbursed for Provenge, and expressed confidence that the recent positive National Coverage Determination (NCD) and assignment of a Q-code would enable increased adoption of the therapy over time. Read More
Medivation Inc., of San Francisco, and Astellas Pharma Inc., of Tokyo, reported results from a preclinical study that the companies said provided evidence that MDV3100, an oral androgen receptor antagonist in clinical development to treat advanced prostate cancer patients, inhibits proliferation of breast cancer cells. Read More
LONDON – Pharming Group NV has the all-clear to start treating patients in the U.S. Phase IIIb study of Rhucin in the treatment of acute attacks of angioedema after reaching agreement with the FDA to expand the trial and modify the way the primary endpoint is assessed. Read More
